Hydroxychloroquine is best known as a long-term treatment for lupus and rheumatoid arthritis, but it also has a real and measurable effect on blood sugar. This article explains how the drug lowers glucose, what the human evidence shows, and why the effect carries a risk of hypoglycemia (abnormally low blood sugar) for people who also take insulin or sulfonylurea tablets. It also describes how prescribers typically adjust glucose monitoring. The effect is usually modest and often helpful. Still, it is real enough that regulators have added it to the drug's official warnings, and it deserves a clear explanation.

From Tree Bark to a Modern Medicine

Hydroxychloroquine belongs to a family of drugs whose story begins with quinine, drawn from the bark of the South American cinchona tree. For centuries quinine was the main defence against malaria. In the twentieth century chemists built synthetic relatives on its structure. Chloroquine came first, in the 1930s. Hydroxychloroquine followed in the 1940s and 1950s as a better-tolerated version. It is a striking example of a remedy found first in the natural world and then refined through careful study.

Physicians soon noticed that the drug calmed the overactive immune responses seen in lupus and rheumatoid arthritis. Today it is a cornerstone of lupus care, and many patients take it for decades. Because so many of these patients also have, or later develop, type 2 diabetes, the drug's effect on glucose matters to a large number of people.

Why Hydroxychloroquine Lowers Blood Glucose

The body regulates glucose through a careful balance. Insulin is released after meals, acts on muscle, fat and liver cells, and is then broken down so its effect does not overshoot. Hydroxychloroquine appears to tip that balance in several ways.

The first of these mechanisms, slower insulin breakdown, rests mostly on cell-culture and animal work. The overall glucose-lowering effect, however, is well documented in humans.

What the Human Evidence Shows

Several kinds of human studies point in the same direction. That consistency is what makes the effect credible.

Observational studies in arthritis patients. A cohort study from the University of Pittsburgh, led by Mary Chester Wasko and published in JAMA in 2007, followed several thousand people with rheumatoid arthritis. Those who had taken hydroxychloroquine had a substantially lower risk of developing diabetes, with a hazard ratio of about 0.62. The protective association grew stronger with longer use. A 2011 JAMA study from Brigham and Women's Hospital, led by Daniel Solomon, also found lower diabetes risk with hydroxychloroquine compared with some other arthritis medicines.

Observational studies cannot fully rule out other explanations. Healthier patients might have been more likely to receive the drug, for example. The consistency of the findings and the plausible mechanism make them persuasive, but they are not proof on their own.

Glycemic control in people who already have diabetes. A 2010 study in Arthritis & Rheumatism by Rekedal and colleagues examined patients with both rheumatoid arthritis and diabetes. Those who started hydroxychloroquine saw larger falls in HbA1c, the standard three-month measure of average blood sugar, than those who started methotrexate.

Randomised trials. The strongest evidence comes from controlled trials, though they are few and fairly small.

On the strength of such evidence, India approved hydroxychloroquine as an add-on treatment for type 2 diabetes in 2014. It is not approved for treating diabetes in the United States, the United Kingdom or the European Union, and it should not be used for that purpose there outside a physician's considered judgement.

Case reports of hypoglycemia. Separately, published case reports describe significant, sometimes severe, hypoglycemia in people taking hydroxychloroquine. A few of these patients did not have diabetes at all. Reports like these led regulators to strengthen the prescribing information. Current labelling warns that the drug can cause severe hypoglycemia, including loss of consciousness, in patients with or without diabetes medicines. It also warns that doses of insulin or other antidiabetic drugs may need to be reduced.

Why Insulin and Sulfonylureas Raise the Stakes

For most people with healthy glucose regulation, the body compensates for a gentle downward push on blood sugar. The pancreas simply releases less insulin. The danger arises when glucose-lowering pressure comes from a source that cannot switch itself off.

Insulin taken by injection or pump keeps working whether or not blood sugar is falling. If hydroxychloroquine slows insulin breakdown and makes cells more responsive, the same dose can produce a larger effect than before.

Sulfonylureas, such as glipizide, glimepiride, glyburide (glibenclamide) and gliclazide, force the pancreas to release insulin regardless of the current glucose level. They already carry a recognised risk of hypoglycemia, and adding a drug that amplifies insulin's action compounds that risk.

By contrast, metformin, DPP-4 inhibitors, SGLT2 inhibitors and GLP-1 receptor agonists rarely cause hypoglycemia on their own. When combined with hydroxychloroquine they are generally a lower concern, though not a zero one.

Several factors raise risk further:

One feature of the drug deserves particular attention: its very long half-life, on the order of several weeks. Its effects build gradually after starting and fade slowly after stopping. A patient may feel fine for the first fortnight and then notice more lows a month or two in. Conversely, blood sugar may drift upward over the weeks after the drug is stopped, and diabetes treatment may need to be stepped back up.

How Prescribers Adjust Monitoring and Treatment

No single protocol is mandated, but practice among rheumatologists, endocrinologists and pharmacists follows a sensible pattern. It works best when the patient is an informed, active partner rather than a passive recipient of instructions.

Pregnancy deserves a specific mention. Hydroxychloroquine is generally continued through pregnancy in women with lupus, because stopping it raises the risk of flares that threaten both mother and child. In women with anti-Ro antibodies, the open-label PATCH study led from New York University, published in Circulation in 2020, found that hydroxychloroquine was associated with a lower recurrence of congenital heart block. The recurrence rate was roughly 7 percent, against a historical rate near 18 percent. Pregnancy also brings shifting insulin needs and, for some women, gestational diabetes treated with insulin. In that setting, careful glucose monitoring protects two lives at once, and close coordination between obstetric, rheumatology and diabetes teams is the norm.

Keeping the Risk in Perspective

For most patients, hydroxychloroquine's effect on glucose is mild, and for many it is a quiet benefit. Lower diabetes risk and better glucose control may contribute to the drug's broader cardiovascular advantages in lupus and rheumatoid arthritis. The point is not to fear the medicine but to understand it. A patient who knows why their readings might change, who records them faithfully, and who brings that information to their own physician is in the strongest position to adjust safely. Good care treats each patient as a whole person, and informed patients working closely with their doctors tend to do best.

Key takeaway: Hydroxychloroquine genuinely lowers blood glucose, so people taking insulin or sulfonylureas should expect closer monitoring and possible dose reductions, particularly in the first few months after starting and again after stopping.